{"pmid":32339701,"title":"Potential role of Janus kinase inhibitors in COVID-19.","text":["Potential role of Janus kinase inhibitors in COVID-19.","J Am Acad Dermatol","Napolitano, Maddalena","Fabbrocini, Gabriella","Patruno, Cataldo","32339701"],"journal":"J Am Acad Dermatol","authors":["Napolitano, Maddalena","Fabbrocini, Gabriella","Patruno, Cataldo"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339701","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaad.2020.04.098","keywords":["covid-19","jak inhibitors","atopic dermatitis","baricitinib","infection","upadacitinib"],"locations":["Janus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1665264685567442946,"score":8.574329,"similar":[{"pmid":32259575,"pmcid":"PMC7128600","title":"Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.","text":["Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.","The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.","Int J Antimicrob Agents","Praveen, D","Puvvada, Ranadheer Chowdary","M, Vijey Aanandhi","32259575"],"abstract":["The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19."],"journal":"Int J Antimicrob Agents","authors":["Praveen, D","Puvvada, Ranadheer Chowdary","M, Vijey Aanandhi"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259575","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijantimicag.2020.105967","keywords":["baricitinib","covid 19","novel corona virus","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","Clarithrin","Janus"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["baricitinib"],"_version_":1664640769836711937,"score":208.99872},{"pmid":32278797,"pmcid":"PMC7144601","title":"The use of Janus kinase inhibitors in the time of SARS-CoV-2.","text":["The use of Janus kinase inhibitors in the time of SARS-CoV-2.","J Am Acad Dermatol","Peterson, Danielle","Damsky, William","King, Brett","32278797"],"journal":"J Am Acad Dermatol","authors":["Peterson, Danielle","Damsky, William","King, Brett"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278797","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.03.099","keywords":["covd-19","janus kinase inhibitors","sars-cov-2","autoimmune disease","coronavirus","general dermatology","immunomodulators","immunosuppressants","medical dermatology"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636873255944193,"score":133.14497},{"pmid":32253068,"pmcid":"PMC7127009","title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","text":["Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.","J Autoimmun","Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo","32253068"],"abstract":["The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19."],"journal":"J Autoimmun","authors":["Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253068","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jaut.2020.102442","keywords":["antimalarials","baricitinib","covid-19","rheumatic diseases","sars-cov2","tocilizumab"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["baricitinib","tocilizumab"],"_version_":1664640769788477440,"score":94.07425},{"pmid":32283223,"title":"Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).","text":["Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).","Pharmacol Res","Abedi, Farshad","Rezaee, Ramin","Karimi, Gholamreza","32283223"],"journal":"Pharmacol Res","authors":["Abedi, Farshad","Rezaee, Ramin","Karimi, Gholamreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283223","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104808","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636703952863234,"score":88.30503},{"pmid":32286678,"title":"Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","text":["Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.","Cardiol J","Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng","32286678"],"abstract":["Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians."],"journal":"Cardiol J","authors":["Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286678","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0056","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme inhibitors","renin-angiotensin system"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636391618772992,"score":80.82777}]}